Please assess the completion status of the following clinical trial:

Trial Title: Study of FYU-981 in Hyperuricemia With or Without Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemic or gout patients~* Serum urate level:~\>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL~Exclusion Criteria:~* Gouty arthritis within two weeks before start of study treatment~* Secondary hyperuricemia~* HbA1c: \>= 8.4%~* Uric acid-overproduction type in the classification of hyperuricemia~* History of, clinically significant cardiac, hematologic and hepatic disease~* Kidney calculi or clinically significant urinary calculi~* eGFR: \< 30mL/min/1.73m\^2~* Systolic blood pressure: \>= 180 mmHg~* Diastolic blood pressure: \>= 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FYU-981 High dose (Type: ACTIVE_COMPARATOR): Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
- FYU-981 High middle dose (Type: ACTIVE_COMPARATOR): Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
- FYU-981 Middle dose (Type: ACTIVE_COMPARATOR): FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
- FYU-981 Low dose (Type: ACTIVE_COMPARATOR): Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).